Genentech Inc. beat expectations for the third quarter and posted strong sales of Lucentis, but weaker-than-expected performance from its oncology franchise cast a shadow over the numbers. (BioWorld Today)

Genentech Inc. beat expectations for the third quarter and posted strong sales of Lucentis, but weaker-than-expected performance from its oncology franchise cast a shadow over the numbers. (BioWorld Today)